TECHNICAL-FINANCIAL REPORT
The performance of the activities of the Pharmaceutical Representatives (ISF) within the structure and public services is ensured and facilitated by the Health Directorates of the AASSLL, of the Universities and of the Institute. Pascale.
To this end, the use of material deposited with AIFA for information to the doctor is permitted (art. 120, Legislative Decree 219/06).
At each visit, the ISFs must deliver to the doctor, for each medicinal product presented, the summary of product characteristics, complete with information on the price and the conditions and limitations under which the product can be placed at the expense of the NHS.
The delivery of CPR (summary of the characteristics of the product) (art. 122, Legislative Decree 219/06) is not necessary if the doctor already has a publication containing the characteristics of the product or if no variations compared to the text included in the aforementioned publication (art. 120, Legislative Decree 219/06).
Without prejudice to all the formalities envisaged for the ISF in the field of pharmacovigilance in the case of information activities, especially in the case of drugs recently introduced on the market and subjected to intensive monitoring, the necessary awareness of the healthcare personnel to the obligations of the regulations contained in Legislative Decree 95/03 must be carried out.
Considering that the drug represents an indispensable health asset for the prevention and restoration of health and that the pharmaceutical sector represents one of the fundamental points in the process of perceived quality of life by citizens.
Considering that the resources that are allocated by the Regional Health Service require careful and continuous verification of quality, ethics and rationality of use for which
Considering that scientific information
